GIKLY News and Press, Grifols SA Barcelona ADR From 01/08/19

BARCELONA, Spain , Jan. 8, 2019 /PRNewswire/ -- Grifols, a leading producer of plasma- derived medicines and recognized leader in transfusion medicine, has received U.S. Food and Drug Administration approval of Erytra Eflexis, a fully automated, benchtop analyzer. The system performs...

BARCELONA, Spain , Oct. 12, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, received approval  from the U.S. Food & Drug Administration ...

BARCELONA, Spain , Oct. 8, 2018 /PRNewswire/ -- The importance of plasma is recognized during International Plasma Awareness Week, October 8-12 . Grifols continues its commitment to plasma-derived medical treatments. These recent developments include: FEBRUARY 2018 : A higher p...

BOWLING GREEN, Ohio , Sept. 24, 2018 /PRNewswire/ -- Grifols is pleased to announce the opening of its newest Biotest Pharmaceuticals Corporation (BPC) plasma donor center located at 1616 East Wooster Street, Bowling Green, Ohio . The 13,000 square foot state-of-the-art facility official...

BARCELONA, Spain , Aug. 14, 2018 /PRNewswire/ --   Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that the U.S. Food and Drug Administration (...

BARCELONA, Spain , June 19, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that it has received approval from the U.S. Food...

The following slide deck was published by Grifols Sa ADR in conjunction with this Read more ...

BARCELONA, Spain , May 31, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the leading companies in the world in plasma-derived biological medicines and transfusion medicine, today announced it is adding a Daratumumab neutralization testing service to its...

BARCELONA, Spain , May 14, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced the expansion of its blood typing solutions portf...

BARCELONA, Spain , April 16, 2018 /PRNewswire/ -- Today, Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced it has donated over 25 million international units (IU) of blood clotting factor medicines over the last year. This donation is part of Grifols' commitment to prov...